Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guardant HealthGH +6.94%66 Debt-to-Equity is -7.61 as of Jun. 2026. GuruFocus rates GH with a GF Score™ of 66/100 and a GF Value™ of $64.85 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Guardant Health ranks worse than 546447.54% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Guardant Health's Debt-to-Equity or its related term are showing as below:
GH'
s Debt-to-Equity Range Over the Past 10 Years
Min: -831.44 Med: 0.05 Max: 22.75
Current: -7.61
During the past 10 years, the highest Debt-to-Equity Ratio of Guardant Health was 22.75. The lowest was -831.44. And the median was 0.05.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Guardant Health Debt-to-Equity Related Terms
Guardant Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Guardant Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Guardant Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (GH) has a Debt-to-Equity of -7.61 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Guardant Health and its competitors. According to the industry distribution chart, Guardant Health ranks #999999 out of 183 companies in the Medical Diagnostics & Research industry.
Is Guardant Health's Debt-to-Equity too high?
Guardant Health's current Debt-to-Equity is -7.61. Based on the distribution chart, Guardant Health ranks #999999 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Guardant Health has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's Debt-to-Equity compare to MEDP and LH?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #999999 out of 183 companies for Debt-to-Equity. This places Guardant Health in the lower half of its industry. The industry median Debt-to-Equity is 0.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.31, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Guardant Health and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardant Health's current Debt-to-Equity is -7.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (GH) is currently considered Significantly Overvalued. The stock's GF Value™ is $64.85, compared to a current price of $168.61 — trading 160% above its estimated fair value. The current Debt-to-Equity is -7.61. Guardant Health's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Guardant Health (GH), the current Debt-to-Equity is -7.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of $168.61 is trading 160% above its estimated GF Value™ of $64.85.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for GH:
Debt-to-Equity: -7.61
GF Value™: $64.85 vs. price of $168.61 (160% above fair value)
No single metric tells the full story. See the GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
66GF Score
Get the complete analysis for GH
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GH has been successfully added to your 
